After years of disappointing ALS clinical trial results, this year's Sheila Essey Award recipient for significant contributions in ALS research is shifting to prevention.
After disappointing phase 3 trial results in ALS, Amylyx will pull Relyvrio from the market but provide it free to patients who want to stay on the medication.
A skin biopsy that can detect an abnormal protein in cutaneous nerve fibers holds promise for early detection of Parkinson's and other neurodegenerative disorders.